Caribou BiosciencesCRBU
About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Employees: 147
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
74% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 27
36% more call options, than puts
Call options by funds: $240K | Put options by funds: $176K
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
6.39% more ownership
Funds ownership: 57.96% [Q3] → 64.35% (+6.39%) [Q4]
3% more funds holding
Funds holding: 128 [Q3] → 132 (+4) [Q4]
10% less capital invested
Capital invested by funds: $103M [Q3] → $93.1M (-$10M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 172 met price target | 1,032%upside $9 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 9 articles about CRBU published over the past 30 days









